Find
News Releases
= add release to Briefcase
| All Releases | |||
|---|---|---|---|
 |
Magnetically Steered Irrigated Tip Cardiac Catheter for Treatment of Irregular Heart Rhythms Now Available Throughout the European Union Nov 18, 2008 |
8.5 KB |
|
|
DIAMOND BAR, Calif., Nov 18, 2008 (BUSINESS WIRE) -- Patients in the European Union (EU) with Atrial Fibrillation and other arrhythmias, also known as irregular heart rhythms, may now benefit from treatment with an innovative state-of-the art catheter. The NAVISTAR(R) RMT THERMOCOOL(R) Catheter is designed to maintain safe ... |
|||
|
New Antibiotic Against Serious Infections - Receives First Approval in Europe Nov 13, 2008 |
9.4 KB |
|
|
Baar, Switzerland (November 13, 2008) - Swissmedic, the Swiss agency for therapeutic products, has approved ZEVTERA™ (ceftobiprole medocaril) for the treatment of complicated skin and soft tissue infections, including diabetic foot infections which have not spread to the bone. Ceftobiprole is licensed from and co-developed with Bas... |
|||
|
Tibotec Data Presented at ICAAC and HIV9 Follow key Regulatory Approvals for Anti-HIV Compounds Nov 12, 2008 |
10.6 KB |
|
|
Glasgow, Scotland (November 12, 2008) - New data on PREZISTA® (darunavir), a protease inhibitor from Tibotec, will be presented at the Ninth International Congress on Drug Therapy in HIV Infection (HIV9) in Glasgow, U.K., from 09-13 November 2008. The company also presented new data on PREZISTA... |
|||
|
Study Finds Catheter Ablation with the NAVISTAR(R) THERMOCOOL(R) Catheter Superior to Anti-Arrhythmic Drug Therapy for the Treatment of Symptomatic, Paroxysmal Atrial Fibrillation Nov 11, 2008 |
9.7 KB |
|
|
NEW ORLEANS, Nov 11, 2008 (BUSINESS WIRE) -- In a multicenter study, catheter ablation has been shown in a randomized clinical trial to significantly outperform anti-arrhythmic drug (AAD) therapy for the treatment of symptomatic paroxysmal atrial fibrillation. Atrial fibrillation, or AFib as it is more commonly referred to, is the most prevalent ca... |
|||
|
Johnson & Johnson-Merck Consumer Pharmaceuticals Company Announces Urgent Voluntary Nationwide Recall of Infants' MYLICON(R) GAS RELIEF DYE FREE Drops (Simethicone-Antigas) Non-Staining Due to Possible Metal Fragments Nov 10, 2008 |
8.4 KB |
|
|
FORT WASHINGTON, Pa., Nov 10, 2008 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson-Merck Consumer Pharmaceuticals Company (JJMCP) is voluntarily recalling approximately 12,000 units of Infants' MYLICON(R) GAS RELIEF DYE FREE drops (simethicone-antigas) non-staining sold in 1 oz. plastic bottles that were distributed after October 5, 2008 ... |
|||
|
Johnson & Johnson to Participate in Credit Suisse 2008 Health Care Conference Nov 6, 2008 |
5.4 KB |
|
|
NEW BRUNSWICK, N.J., Nov 06, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will participate in the Credit Suisse 2008 Health Care Conference on Thursday, Nov. 13, at the Arizona Biltmore Hotel. Donald M. Casey, Worldwide Chairman of Johnson & Johnson's Comprehensive Care Group, will present in a session scheduled at 10:30... |
|||
|
Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder Nov 1, 2008 |
13.1 KB |
|
|
SAN DIEGO, Nov 01, 2008 /PRNewswire via COMTEX News Network/ -- Patients with schizoaffective disorder receiving paliperidone extended release tablets (paliperidone ER) for six weeks showed a significant improvement in their symptoms, according to a new study presented today at the U.S. Psychiatric & Mental Health Congress in San Diego, Calif.(1) I... |
|||
|
TCT2008 Concludes with Presentation of Positive Data for the CYPHER(R) Sirolimus-eluting Coronary Stent Oct 30, 2008 |
8.8 KB |
|
|
WARREN, N.J., Oct 30, 2008 (BUSINESS WIRE) -- This year's Transcatheter Cardiovascular Therapeutics annual meeting, also known as TCT2008, concluded recently with two important data presentations on studies that resulted in significant clinical differences between the CYPHER(R) Sirolimus-eluting Coronary Stent and Medtronic's Endeavor(R) Stent. In ... |
|||
|
Johnson & Johnson Establishes Wellness & Prevention Platform with Acquisition of HealthMedia, Inc. Oct 27, 2008 |
7.1 KB |
|
|
NEW BRUNSWICK, N.J., Oct 27, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- As an initial step in the creation of a wellness and prevention business platform, Johnson & Johnson announced today it has acquired HealthMedia, Inc., a privately held company located in Ann Arbor, Michigan, that creates web-based behavior change interventions. Ter... |
|||
|
New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria Oct 27, 2008 |
12.6 KB |
|
|
WASHINGTON, Oct 27, 2008 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), today announced new study results that demonstrate doripenem (DORIBAX(TM), doripenem for injection), a carbapenem antibiotic, was found to be more potent in vitro against certain strains of Enterobacteriaceae, i... |
|||
|
Golimumab Phase 3 Data Show Significant Improvement in Physical Function in Patients with Rheumatoid Arthritis Oct 27, 2008 |
19.3 KB |
|
|
SAN FRANCISCO, Calif., October 27, 2008 - Results from two Phase 3 studies showed that patients receiving every four week subcutaneous injections of golimumab (CNTO 148) 50 mg or 100 mg, an investigational therapy, experienced significant improvements in physical function, health-related quality of life (HRQOL) and fatigue. The data from ... |
|||
|
Patient Enrollment Complete for Pivotal Trial of the NEVO(TM) Sirolimus-eluting Coronary Stent with Unique Reservoir Technology Oct 27, 2008 |
10.6 KB |
|
|
WARREN, N.J., Oct 27, 2008 (BUSINESS WIRE) -- Cordis Corporation and Conor Medsystems, LLC announced today that patient enrollment has been completed for a randomized clinical trial comparing the NEVO(TM) Sirolimus-eluting Coronary Stent, a new cobalt chromium reservoir-based stent design, to the Taxus(R) Liberte(R) Paclitaxel-eluting Coronary Sten... |
|||
|
One-Year Data Show Golimumab Improved Signs and Symptoms in Patients with Psoriatic Arthritis in Phase 3 Study Oct 27, 2008 |
18.4 KB |
|
|
SAN FRANCISCO, Calif., October 27, 2008 - More than half of patients receiving every four week subcutaneous injections of golimumab (CNTO 148) 50 mg and 100 mg, an investigational therapy, experienced sustained improvements in the joint and skin symptoms of active psoriatic arthritis through six months with results sustained through one y... |
|||
|
FDA Clears VITROS® 5600 Integrated System for Laboratory Diagnostics Oct 24, 2008 |
7.8 KB |
|
|
Raritan, NJ (October 24, 2008) – Ortho Clinical Diagnostics today announced 510(k) clearance from the United States Food and Drug Administration (FDA) for its VITROS® 5600 Integrated System. This next generation system is uniquely designed to integrate clinical chemistry and immunoassay testing to increase laboratory productivity and will be a... |
|||
|
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Carisbamate Oct 24, 2008 |
8.9 KB |
|
|
RARITAN, N.J., Oct 24, 2008 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that it has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for carisbamate, a new investigational compound for the adjunctive treatment of partial onset seizure... |
|||
|
U.S. Food and Drug Administration (FDA) Approves PREZISTA® Once-Daily as Part of Combination Therapy for Treatment-Naïve Adults with HIV-1 Oct 22, 2008 |
69.2 KB |
|
|
[Bridgewater, NJ, October 21, 2008] - The FDA has granted PREZISTA®(darunavir) tablets, a protease inhibitor, approval for an expanded indication for once-daily dosing as part of HIV combination therapy in treatment-naïve adults (those who have never taken HIV medication before). The FDA also granted traditional (full) approval t... |
|||
|
Ethicon Endo-Surgery Completes Acquisition of SurgRx, Inc. Oct 17, 2008 |
7.8 KB |
|
|
CINCINNATI, October 16, 2008 - Ethicon Endo-Surgery announced today that it has completed the acquisition of SurgRx, Inc., following clearance under the Hart-Scott-Rodino Antitrust Improvement Act and similar regulations in other countries. SurgRx, Inc. is a privately held developer of the advanced bipolar tissue sealing system used in th... |
|||
|
Tibotec Begins Enrollment for Phase III Study of Telaprevir, an Investigational Agent, in HCV Patients Who Failed Prior Treatment Oct 15, 2008 |
9.0 KB |
|
|
Mechelen, Belgium (October 15, 2008) - Tibotec BVBA announced today that it has begun enrolling patients in its phase III clinical trial evaluating telaprevir, an investigational hepatitis C virus protease inhibitor, in patients who failed prior therapy with peginterferon (Peg-IFN) plus ribavarin (RBV). The trial, known as REALIZE, will compare ... |
|||
|
Johnson & Johnson Reports 2008 Third-Quarter Results Oct 14, 2008 |
35.2 KB |
|
|
NEW BRUNSWICK, N.J., Oct 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sales of $15.9 Billion Increased 6.4% Versus a Year Ago; EPS was $1.17 Excluding 2007 Special Items, 2008 Third-Quarter EPS Increased 10.4%* Johnson & Johnson today announced sales of $15.9 billion for the third quarter of 2008, an increase of 6.4% as compar... |
|||
|
FDA Approves New Injection Site for RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment Oct 9, 2008 |
12.0 KB |
|
|
TITUSVILLE, N.J., Oct 09, 2008 /PRNewswire via COMTEX News Network/ -- TITUSVILLE, N.J., Oct. 9 /PRNewswire-FirstCall/ -- Patients with schizophrenia now have a new administration option for RISPERDAL(R) CONSTA(R) ([risperidone] Long-Acting Injection). The U.S. Food and Drug Administration (FDA) has approved a new injection site, the deltoid muscle... |
|||
= add release to Briefcase
